Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.57 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.57 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.57 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.57 |
| ▸ | POLA1 | P09884 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.47 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.41 |
| ▸ | CDA | P32320 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8749574 | 1.00 | SLC29A1 (0.57) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL1763360 | 1.00 | SLC29A1 (0.57) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL7876363 | 1.00 | SLC29A1 (0.57) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| Hydrochloric Acid SCHEMBL29938288 | 0.99 | SLC29A1 (0.56) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| Phosphoric Acid SCHEMBL20769291 | 0.95 | SLC28A1 (0.53) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| Phosphoric Acid SCHEMBL4575893 | 0.95 | SLC28A1 (0.53) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| Phosphoramidic Acid SCHEMBL17439381 | 0.93 | SLC29A1 (0.51) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL12170413 | 0.88 | SLC29A1 (0.59) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL6758716 | 0.88 | SLC29A1 (0.59) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 | |
| SCHEMBL94634 | 0.88 | SLC29A1 (0.59) | SLC29A1SLC28A1SLC28A2SLC28A3POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3753 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| US-20260139251-A1 | RNAi Agents for Inhibiting Expression of Mucin 5AC (MUC5AC), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| US-20260132406-A1 | RNAi Agents for Inhibiting Expression of Activin Receptor-Like Kinase 7 (ALK7), Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4739343-A2 | CIRCULAR RNA VACCINES FOR SEASONAL FLU AND METHODS OF USES | Shanghai Circode Biomed Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-20260092276-A1 | Carbohydrate-oligonucleotide conjugates, pharmaceutical compositions, and therapeutic applications | KYLONOVA XIAMEN BIOPHARMA CO LTD (CN) | 2026-04-02 | — | — | US | claimed |
| US-12582668-B2 | Methods for the treatment of alpha-1 antitrypsin deficiency (AATD) | Arrowhead Pharmaceuticals, Inc. (US) | 2026-03-24 | — | — | US | claimed |
| US-20260078375-A1 | RNAi Agents for Inhibiting Influenza A Viral Gene Expression, Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-19 | — | — | US | claimed |
| EP-3573623-B1 | COMPOSITIONS AND METHODS FOR INHIBITION OF FACTOR XII GENE EXPRESSION | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-03-04 | — | — | EP | claimed |
| US-20260053941-A1 | MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2026-02-26 | — | — | US | claimed |
| US-12551569-B2 | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | claimed |
| US-20020151072-A1 | Chimeric mutational vectors | VALIGEN (U.S), INC. | 2002-10-17 | — | — | US | claimed |
| EP-1078097-A4 | CELL-FREE CHIMERAPLASTY AND EUKARYOTIC USE OF HETERODUPLEX MUTATIONAL VECTORS | KIMERAGEN INC (US) | 2002-06-05 | — | — | EP | claimed |
| EP-1084272-A4 | HETERODUPLEX MUTATIONAL VECTORS AND USE THEREOF IN BACTERIA | KIMERAGEN INC (US) | 2002-03-13 | — | — | EP | claimed |
| US-6211351-B1 | FOR INTRODUCTION OF GENETIC CHANGES IN EUKARYOTIC CELLS | VALIGEN (US), INC. | 2001-04-03 | — | — | US | claimed |
| EP-1084272-A1 | HETERODUPLEX MUTATIONAL VECTORS AND USE THEREOF IN BACTERIA | Kimeragen Inc. (US) | 2001-03-21 | — | — | EP | claimed |
| EP-1078097-A1 | CELL-FREE CHIMERAPLASTY AND EUKARYOTIC USE OF HETERODUPLEX MUTATIONAL VECTORS | Kimeragen Inc. (US) | 2001-02-28 | — | — | EP | claimed |
| US-6010907-A | TRANSFORMING TARGET DNA SEQUENCES | KIMERAGEN, INC. (US) | 2000-01-04 | — | — | US | claimed |
| US-6004804-A | 3'-EXONUCLEASE PROTECTED DUPLEX MUTATIONAL VECTORS; USED TO MAKE SPECIFIC GENETIC ALTERATIONS IN THE GENOME AND IN PLASMIDS OF TARGET PROKARYOTIC CELLS | KIMERAGEN, INC. (US) | 1999-12-21 | — | — | US | claimed |
| WO-1999058723-A1 | HETERODUPLEX MUTATIONAL VECTORS AND USE THEREOF IN BACTERIA | KIMERAGEN, INC. (US) | 1999-11-18 | — | — | WO | claimed |
| WO-1999058702-A1 | CELL-FREE CHIMERAPLASTY AND EUKARYOTIC USE OF HETERODUPLEX MUTATIONAL VECTORS | KIMERAGEN, INC. (US) | 1999-11-18 | — | — | WO | claimed |